

WHAT IS CLAIMED IS:

1. A method for treating lung cancer in a patient consisting essentially of administering to said patient a therapeutically effective amount of insulin-like growth factor binding protein-3 (IGFBP-3).
2. The method of claim 1, wherein said therapeutically effective amount of IGFBP-3 is administered parenterally.
3. The method of claim 2, wherein said therapeutically effective amount of IGFBP-3 is administered via subcutaneous injection.
4. The method of claim 2, wherein said therapeutically effective amount of IGFBP-3 is administered intravenously.
5. The method of claim 2, wherein said therapeutically effective amount of IGFBP-3 is administered via intravenous infusion.
6. The method of claim 1, wherein said therapeutically effective amount of IGFBP-3 is about 0.1 mg/kg to 40 mg/kg of body weight.
7. The method of claim 1, wherein said therapeutically effective amount of IGFBP-3 is about 0.25 mg/kg to 5 mg/kg of body weight.
8. The method of claim 1, wherein said IGFBP-3 is nonglycosylated.
9. The method of claim 1, wherein a cytotoxic and/or chemotherapeutic agent is not co-administered with IGFBP-3.